Pharming Group N.V. Files Form 6-K

TL;DR

Pharming Group N.V. filed a 6-K with an attached press release on Oct 24, 2024. Details inside.

AI Summary

Pharming Group N.V. filed a Form 6-K on October 24, 2024, to furnish a press release dated October 24, 2024. The filing itself does not contain specific financial figures or operational updates beyond referencing the attached press release.

Why It Matters

This filing indicates that Pharming Group N.V. is providing an update to the SEC, likely containing important information for investors that was released to the public.

Risk Assessment

Risk Level: low — This is a routine filing to furnish a press release, not containing new material financial information within the 6-K itself.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• October 24, 2024 (date) — Filing and Press Release Date

FAQ

Key Financial Figures

• $74.8 m — 24 total revenues increased by 12% to US$74.8 million, compared to the third quarter 20
• $63.6 m — d quarter revenu e increased by 6% to US$63.6 million, compared to the third quarter 20
• $11.2 m — quarter reven ue increased b y 72% to US$11.2 million, compared to the third quarter 20
• $204.5 m — s total revenu es increased by 25% to US$204.5 million, compared to the first nine month
• $280 million — k for 2 024 total revenue guidance of US$280 million - US$295 million (14 - 20% growth) Thi
• $295 million — revenue guidance of US$280 million - US$295 million (14 - 20% growth) Third quarter operat
• $4.1 million — quarter operating profit increased to US$4.1 million from US$1.9 million in the third quarte
• $1.9 million — ofit increased to US$4.1 million from US$1.9 million in the third quarter 2023 Overall cash
• $173.3 million — nd marketable securities increased to US$173.3 million at the end of the third quarter 2024 fr
• $161.8 million — he end of the third quarter 2024 from US$161.8 million at the end of the second quarter 2024
• $74.8 million — erly revenues by 12% to a record-high US$74.8 million and also achieving record revenues of U
• $204.5 million — and also achieving record revenues of US$204.5 million for the first nine months of the year.
• $172.6 m — for the first nine months of 2024 was US$172.6 million, a 12% increase compared to the s
• $11.2 million — of APDS Joenja revenues increased to US$11.2 million in the third quarter of 2024, a 72% inc
• $31.9 m — for the first nine months of 2024 was US$31.9 million, compared to US$10.3 million for

Filing Documents

• a2024q3pressrelease.htm (6-K) — 388KB
• logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
• logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
• 0001828316-24-000035.txt ( ) — 556KB

Forward-looking Statements

Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their 8 entirety by the cautionary statements contained or referre

View Full Filing

View this 6-K filing on SEC EDGAR